Duloxetine Capsule, Delayed Release
Product Images NDC 71335-2567

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71335-2567). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 01)

FDA Label Image

Figure 1 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 02)

This text provides information related to the proportion of patients with relapse in a study comparing placebo to duloxetine treatment over a specific time period (in days). The data is presented in a table or graph format, showing the outcomes for patients at different time points from randomization to relapse. The Kaplan-Meier estimator method is used for the analysis.*

FDA Label Image

Figure 2 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 03)

This text provides data on the proportion of patients experiencing a relapse over time for both a placebo and duloxetine treatment. The information is presented in a table with the time from randomization to relapse in days. The data seems to have been analyzed using the Kaplan-Meier estimator method.*

FDA Label Image

Figure 1 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 04)

This information appears to be presenting data regarding the percentage of patients who experienced improvement while taking different dosages of Duloxetine and Placebo. It mentions the percentage of patients improved with Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and Placebo. The table likely includes data on the percent improvement in pain from the baseline.*

FDA Label Image

Figure 2 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 05)

Percentage of Patients Improved: R = 1 Percent Improvement in Pain from Baseline: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Placebo.*

FDA Label Image

Fig 5 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 06)

Percentage of Patients Improved with Duloxetine 60 mg Twice Daily, Duloxetine 60 mg Once Daily, and Placebo based on the different levels of pain improvement from the baseline. The chart shows the percentage of patients who experienced various levels of pain improvement, ranging from less than 10% to 100%.*

FDA Label Image

Fig 6 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 07)

This text provides information on the percentage of patients who experienced improvement in pain after taking different doses of Duloxetine and placebo. The data is represented in a table showing the level of improvement in increments from 10 to 100%. The highest improvement is seen with Duloxetine 120 mg taken twice daily.*

FDA Label Image

Fig 7 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 08)

This text provides information on the percentage of pediatric patients aged 13 to 17 years old with Juvenile Fibromyalgia Syndrome achieving various levels of pain relief at week 12 in a study (FM-4). The study compares the effectiveness of Duloxetine 60mg once daily versus a placebo. The pain relief was measured using the Brief Pain Inventory - Modified Short Form: Adolescent Version Average Pain Score. Duloxetine-treated patients started with 30mg once daily for a week and then titrated to 60mg once daily for 12 weeks.*

FDA Label Image

Figure 8 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 09)

This data represents the percentage of patients improved with Duloxetine 60/120 mg once daily compared to a Placebo, as per the Percent Improvement in Pain from Baseline analysis. The chart ranges from 0 to 100, showing the level of improvement in pain reported by patients.*

FDA Label Image

Figure 9 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 10)

This is a chart displaying the percentage of patients improved with Duloxetine 60 mg compared to a placebo. The improvement is measured on a scale showing percentage improvement in pain from baseline. The chart indicates that 100% of patients experienced improvement when taking Duloxetine 60 mg once daily.*

FDA Label Image

Figure 10 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 11)

This text provides information on the percentage of patients improved in a study comparing a placebo to Duloxetine at 60/120 mg dosage. It includes a chart showing the percentage improvement in pain from baseline. The data indicates that the Duloxetine treatment showed significant improvement compared to the placebo.*

FDA Label Image

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 935 1)

FDA Label Image

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 942 1)

FDA Label Image

Label (Lbl713352567)

This text is a description of medication containing Duloxetine Hydrochloride in delayed-release capsules. It provides information on the dosage, storage conditions, manufacturer details, and instructions for pharmacists on dispensing the medication. It also mentions the National Drug Code (NDC) for the product. Make sure to check the package insert QR code for detailed dosage information.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.